Table 1 Subjects’ clinical characteristics

Number of subjects

20

20

Months since BT*

–

23 (15)

Age (years)^†

47 ± 2

49 ± 2

Sex (M/F)

8/12

8/12

Smoking status (no/ex/yes)

13/6/1

13/6/1

Atopy (no/yes)

6/14

6/14

Inhaled corticosteroid dose (µg)^†,§

1275 ± 175

938 ± 166

Median (range)

1375 (0–3000)

750 (0–3000)

Long acting β₂-agonist (µg)^†,ll

114 ± 14

102 ± 13

Median (range)

100 (0–250)

100 (0–200)

Oral corticosteroids (n)

4 (7.5–30.0)

3 (5.0–10.0)

Omalizumab (n)

3

3

Mepolizumab (n)

1

2

Montelukast (n)

9

8

Post-BD FEV₁ (L)^†

2.66 ± 0.18

2.83 ± 0.19

Count of severe exacerbations^‡

1 (0–10)

0 (0–2)

ACSS^†

71 ± 4

88 ± 3